Related Experiment Video

Updated: Jun 8, 2026

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

Role of olmesartan in combination therapy in blood pressure control and vascular function

Carlos M Ferrario1, Ronald D Smith

  • 1Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. cferrari@wfubmc.edu

Vascular Health and Risk Management
|September 23, 2010
PubMed

Insights

Fixed-dose combinations of angiotensin receptor blockers and amlodipine are effective for managing hypertension. This therapy improves blood pressure control, vascular function, and reduces target organ damage, enhancing patient adherence.

Area of Science:

  • Cardiology
  • Pharmacology
  • Nephrology

Background:

  • Angiotensin receptor blockers (ARBs) are first-line hypertension treatments.
  • Guidelines recommend strict blood pressure control (<140/90 mmHg or <130/80 mmHg for comorbidities).
  • Achieving these goals often requires combination therapy.

Purpose of the Study:

  • To review evidence on ARB and amlodipine combination therapy.
  • To assess effects on blood pressure control.
  • To evaluate improvements in vascular function and target organ damage.

Main Methods:

  • Review of clinical evidence on ARB and amlodipine fixed-dose combinations.
  • Analysis of studies focusing on renin-angiotensin system blockade.
  • Assessment of outcomes related to blood pressure, vascular health, and organ damage.

Main Results:

  • Combination therapy with ARBs and amlodipine provides additive antihypertensive effects.
  • This combination demonstrates a safe profile and improves patient adherence.
  • Evidence supports benefits in blood pressure control and vascular function.

Conclusions:

  • Fixed-dose ARB-amlodipine combinations are effective for hypertension management.
  • This therapy aids in achieving guideline-recommended blood pressure goals.
  • Benefits extend to improved vascular function and reduced target organ damage.

Keywords:
amlodipineangiotensin receptor blockersangiotensin-converting enzyme 2hypertensionrenin–angiotensin system

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...